Erasca, Inc. Operating Cash Flow
Erasca, Inc. (ERAS) reported Operating Cash Flow of -$54.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Erasca, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$27.27M.
- Erasca, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$27.38M.
- Erasca, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$21.71M.
- Erasca, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$21.66M.
- Erasca, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$95.45M.
- Erasca, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$109.42M.
- Erasca, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$101.22M.
- Erasca, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$103.26M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$27.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$54.65M 10-Q · filed 2026-08-11 | -$76.36M derived: sum of 3 quarters · filed 2026-08-11 | -$98.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$27.38M 10-Q · filed 2026-05-11 | -$49.09M derived: sum of 2 quarters · filed 2026-05-11 | -$70.75M derived: sum of 3 quarters · filed 2026-05-11 | -$91.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$21.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$43.37M derived: sum of 2 quarters · filed 2026-03-12 | -$63.90M derived: sum of 3 quarters · filed 2026-08-11 | -$95.45M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$21.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$42.19M derived: sum of 2 quarters · filed 2026-08-11 | -$73.74M 10-Q · filed 2025-11-12 | -$98.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$20.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$52.09M 10-Q · filed 2026-08-11 | -$76.65M derived: sum of 3 quarters · filed 2026-08-11 | -$99.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$31.55M 10-Q · filed 2026-05-11 | -$56.12M derived: sum of 2 quarters · filed 2026-05-11 | -$78.54M derived: sum of 3 quarters · filed 2026-05-11 | -$107.72M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$24.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$46.98M derived: sum of 2 quarters · filed 2026-03-12 | -$76.17M derived: sum of 3 quarters · filed 2026-03-12 | -$109.42M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$22.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$51.60M derived: sum of 2 quarters · filed 2025-11-12 | -$84.85M 10-Q · filed 2025-11-12 | -$109.64M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$29.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$62.43M 10-Q · filed 2025-08-12 | -$87.22M derived: sum of 3 quarters · filed 2025-08-12 | -$111.34M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$33.25M 10-Q · filed 2025-05-13 | -$58.04M derived: sum of 2 quarters · filed 2025-05-13 | -$82.16M derived: sum of 3 quarters · filed 2025-05-13 | -$108.11M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$24.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$48.91M derived: sum of 2 quarters · filed 2025-03-20 | -$74.86M derived: sum of 3 quarters · filed 2025-03-20 | -$101.22M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$24.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$50.07M derived: sum of 2 quarters · filed 2024-11-12 | -$76.43M 10-Q · filed 2024-11-12 | -$102.80M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$25.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$52.31M 10-Q · filed 2024-08-12 | -$78.68M derived: sum of 3 quarters · filed 2024-08-12 | -$102.63M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$26.36M 10-Q · filed 2024-05-08 | -$52.73M derived: sum of 2 quarters · filed 2024-05-08 | -$76.67M derived: sum of 3 quarters · filed 2024-05-08 | -$103.82M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$26.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$50.32M derived: sum of 2 quarters · filed 2024-03-27 | -$77.46M derived: sum of 3 quarters · filed 2024-03-27 | -$103.26M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$23.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$51.09M derived: sum of 2 quarters · filed 2023-11-09 | -$76.89M 10-Q · filed 2023-11-09 | -$99.37M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$27.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$52.95M 10-Q · filed 2023-08-10 | -$75.43M derived: sum of 3 quarters · filed 2023-08-10 | -$98.65M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$25.81M 10-Q · filed 2023-05-15 | -$48.29M derived: sum of 2 quarters · filed 2023-05-15 | -$71.51M derived: sum of 3 quarters · filed 2023-05-15 | -$89.74M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$22.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$45.70M derived: sum of 2 quarters · filed 2023-03-23 | -$63.93M derived: sum of 3 quarters · filed 2023-03-23 | -$79.60M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$23.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$41.45M derived: sum of 2 quarters · filed 2022-11-09 | -$57.12M 10-Q · filed 2022-11-09 | -$70.21M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$18.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$33.90M 10-Q · filed 2022-08-11 | -$46.99M derived: sum of 3 quarters · filed 2022-08-11 | -$54.47M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$15.67M 10-Q · filed 2022-05-12 | -$28.76M derived: sum of 2 quarters · filed 2022-05-12 | -$36.24M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$20.57M derived: sum of 2 quarters · filed 2022-03-24 | -$32.69M 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$7.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$19.59M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$12.12M 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |